Printer Friendly

CStone Pharmaceuticals names new senior vice president, chief translational medicine officer.

M2 PHARMA-December 10, 2018-CStone Pharmaceuticals names new senior vice president, chief translational medicine officer

(C)2018 M2 COMMUNICATIONS

CStone Pharmaceuticals, a biopharma company focused on developing and commercialising innovative immuno-oncology and molecularly targeted drugs, announced today that it has named Archie Tse, MD, PhD as its new senior vice president, chief translational medicine officer.

Dr Tse is to report to Frank Jiang, MD, PhD, chairman and chief executive officer.

Dr Tse has more than 20 years of global oncology research and clinical development experience and the company says that he will provide a strong addition to its senior leadership team. In this role, Dr Tse will be responsible for the development of assets at the early clinical development stage up to proof of concept. He will manage the development and implementation of clinical biomarkers to support progression of CStone's pipelines. His in-depth understanding of the global oncology space is intended to help further strengthen CStone's core competence and solidify its position among innovative biopharma companies in China.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 10, 2018
Words:178
Previous Article:Aurora Cannabis collaborates with Farmacias Magistrales.
Next Article:Tenax Therapeutics expects USD10m from underwritten offering of 5,181,346 units.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters